Aushon is planning to launch its new multiplex protein biomarker platform, which the company says incorporates several engineering breakthroughs to deliver ELISA-level performance.
Aushon's microarray printing, novel assay design, astronomy-grade imaging and advanced analytics provide the sensitivity and reproducibility of single-plexed ELISA in a multiplexed format.
The technology is expected to help scientists who have been unable to find a multiplexing solution that consistently delivers the required performance in their studies.
Aushon founder and CEO Pete Honkanen said based on feedback gathered over the past several years, scientists in general have been dissatisfied with the performance of earlier generation multiplex systems.
"They love the idea of what multiplexing can deliver in terms of overall lab productivity, reduced sample consumption and lower cost per study but are seeing relatively poor performance vis-a-vis traditional ELISA...which has constrained the growth in the use of these platforms in the protein biomarker market. We're confident that we've addressed that issue," Honkanen said.
Aushon said it has already placed systems with several early adopters at Big Pharma and leading academic institutions including Duke University Medical Center.
The company will sell the platform through Aushon's direct sales team in North America and Europe.
